Published Date: 24 Jul 2025
A new study has explored how people with hereditary cancer identify on TikTok.
Read Full NewsThe rheumatology year in review highlights FDA approvals and pivotal data readouts.
Johnson & Johnson plans to initiate a phase 3 study based off the positive data.
Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.
Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.
The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.
Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101
Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression
1.
A Lot Can Be Said About You by Including Yourself in Photos.
2.
Black women have a higher risk of dying from all types of breast cancer, meta-analysis reveals
3.
Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.
4.
Year in Review: Non-Small Cell Lung Cancer
5.
Shorter, less intense regimen still effective for HPV-linked throat cancer, study shows
1.
Hematologic Toxicity of CDK4/6 Inhibitors in Breast Cancer: Meta-Analysis and Safety Data
2.
Unraveling the Mysteries of Burkitt Lymphoma: A New Hope for Treatment
3.
The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy
4.
Therapeutic Innovations Through Germline Predisposition in Acute Leukemias and Myeloid Neoplasms
5.
Liquid Biopsy: Revolutionizing Precision Oncology in Hematological Malignancies
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
2.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
4.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
5.
Learning About Different Treatment Approaches For Acute Lymphoblastic Leukemia
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation